Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
Astria Therapeutics (Nasdaq:ATXS) announced two poster presentations at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Boston on October 25, 2024. The presentations focus on Hereditary Angioedema (HAE) and quality of life data:
1. Dr. Aleena Banerji will present new quality of life data from the Phase 1b/2 trial of navenibart (STAR-0215) in a poster titled 'STAR-0215 Induces Rapid Improvements of Quality of Life in HAE Patients in the ALPHA-STAR Trial' at 3:30pm EST.
2. Dr. Donald Levy will present Astria-sponsored research on 'Quality of Life and Burden of Disease in Patients with Hereditary Angioedema and their Caregivers' at 3:45pm EST.
Both presentations will take place in Exhibit Hall A, highlighting Astria's commitment to developing therapies for allergic and immunologic diseases.
Astria Therapeutics (Nasdaq:ATXS) ha annunciato due presentazioni su poster presso il Congresso Scientifico Annuale del Collegio Americano di Allergia, Asma e Immunologia (ACAAI) a Boston, il 25 ottobre 2024. Le presentazioni si concentrano su Angioedema Ereditario (HAE) e dati sulla qualità della vita:
1. La Dr.ssa Aleena Banerji presenterà nuovi dati sulla qualità della vita della fase 1b/2 dello studio navenibart (STAR-0215) in un poster intitolato 'STAR-0215 Induce Rapidi Miglioramenti della Qualità della Vita nei Pazienti con HAE nell'Esperimento ALPHA-STAR' alle 15:30 EST.
2. Il Dr. Donald Levy presenterà una ricerca sponsorizzata da Astria su 'Qualità della Vita e Onere della Malattia nei Pazienti con Angioedema Ereditario e nei loro Caregiver' alle 15:45 EST.
Entrambe le presentazioni si svolgeranno nella Hall A, evidenziando l'impegno di Astria nello sviluppo di terapie per malattie allergiche e immunologiche.
Astria Therapeutics (Nasdaq:ATXS) anunció dos presentaciones en póster en la Reunión Científica Anual del Colegio Americano de Alergia, Asma e Inmunología (ACAAI) en Boston, el 25 de octubre de 2024. Las presentaciones se centran en Angioedema Hereditario (HAE) y datos sobre la calidad de vida:
1. La Dra. Aleena Banerji presentará nuevos datos sobre la calidad de vida del ensayo de fase 1b/2 de navenibart (STAR-0215) en un póster titulado 'STAR-0215 Induce Mejora Rápida de la Calidad de Vida en Pacientes con HAE en el Ensayo ALPHA-STAR' a las 3:30pm EST.
2. El Dr. Donald Levy presentará una investigación patrocinada por Astria sobre 'Calidad de Vida y Carga de la Enfermedad en Pacientes con Angioedema Hereditario y sus Cuidadores' a las 3:45pm EST.
Ambas presentaciones tendrán lugar en el Salón de Exposiciones A, destacando el compromiso de Astria en el desarrollo de terapias para enfermedades alérgicas e inmunológicas.
Astria Therapeutics (Nasdaq:ATXS)는 2024년 10월 25일 보스턴에서 열리는 미국 알레르기, 천식 및 면역학 회의(ACAAI) 연례 과학 회의에서 두 가지 포스터 발표를 발표했습니다. 발표는 유전성 혈관부종(HAE)와 삶의 질 데이터에 초점을 맞추고 있습니다:
1. 알리나 바네르지 박사가 navenibart (STAR-0215)의 1b/2상 시험에서 새로운 삶의 질 데이터를 발표하며, 포스터 제목은 'STAR-0215가 ALPHA-STAR 시험에서 HAE 환자의 삶의 질을 빠르게 개선시킨다'입니다. 발표는 오후 3시 30분 EST에 진행됩니다.
2. 도널드 레비 박사가 '유전성 혈관부종 환자와 그 보호자의 삶의 질 및 질병 부담'에 관한 Astria 후원 연구를 오후 3시 45분 EST에 발표합니다.
두 발표 모두 전시 홀 A에서 진행되며, 알레르기 및 면역 질환 치료제를 개발하려는 Astria의 의지를 강조합니다.
Astria Therapeutics (Nasdaq:ATXS) a annoncé deux présentations sous forme de posters lors de la Réunion Scientifique Annuelle du Collège Américain d'Allergie, d'Asthme et d'Immunologie (ACAAI) à Boston, le 25 octobre 2024. Les présentations se concentrent sur Angio-œdème Héréditaire (HAE) et des données sur la qualité de vie :
1. La Dr Aleena Banerji présentera de nouvelles données sur la qualité de vie issues de l'essai de phase 1b/2 du navenibart (STAR-0215) dans un poster intitulé 'STAR-0215 Induit des Améliorations Rapides de la Qualité de Vie chez les Patients HAE dans l'Essai ALPHA-STAR' à 15h30 EST.
2. Le Dr Donald Levy présentera une recherche parrainée par Astria sur 'Qualité de Vie et Charges de Maladie chez les Patients atteint d'Angio-œdème Héréditaire et leurs Aidants' à 15h45 EST.
Les deux présentations auront lieu dans le Hall d'Exposition A, mettant en avant l'engagement d'Astria dans le développement de thérapies contre les maladies allergiques et immunologiques.
Astria Therapeutics (Nasdaq:ATXS) gab zwei Poster-Präsentationen beim Jahreskongress des Amerikanischen Kollegen für Allergie, Asthma und Immunologie (ACAAI) in Boston am 25. Oktober 2024 bekannt. Die Präsentationen konzentrieren sich auf Erbliches Angioödem (HAE) und Daten zur Lebensqualität:
1. Dr. Aleena Banerji wird neue Daten zur Lebensqualität aus der Phase 1b/2-Studie von navenibart (STAR-0215) in einem Poster mit dem Titel 'STAR-0215 induziert schnelle Verbesserungen der Lebensqualität bei HAE-Patienten in der ALPHA-STAR-Studie' um 15:30 Uhr EST präsentieren.
2. Dr. Donald Levy wird eine von Astria gesponserte Forschung zu 'Lebensqualität und Krankheitslast bei Patienten mit Erblichen Angioödemen und deren Betreuern' um 15:45 Uhr EST vorstellen.
Beide Präsentationen finden in der Ausstellungshalle A statt und unterstreichen Astrias Engagement für die Entwicklung von Therapien gegen allergische und immunologische Erkrankungen.
- None.
- None.
Dr. Aleena Banerji, M.D., Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Allergy and Immunology Unit at Massachusetts General Hospital, will present new quality of life data from initial results from the Phase 1b/2 trial of navenibart (STAR-0215) in a presentation of a poster titled “STAR-0215 Induces Rapid Improvements of Quality of Life in HAE Patients in the ALPHA-STAR Trial.” The presentation will take place in Exhibit Hall A on Friday, October 25 at 3:30pm EST.
Astria sponsored additional quality of life research in people living with HAE that will be presented by Dr. Donald Levy, M.D., Health Sciences Professor of Medicine in the Division of Basic and Clinical Immunology at the University of
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241021639207/en/
Astria:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
When and where will Astria Therapeutics (ATXS) present at the ACAAI Annual Scientific Meeting?
What is the focus of Astria Therapeutics' (ATXS) presentations at the ACAAI meeting?
Who will be presenting the posters for Astria Therapeutics (ATXS) at the ACAAI meeting?
What is navenibart (STAR-0215) and how does it relate to Astria Therapeutics (ATXS)?
